Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study

BACKGROUND: Severe and critically-ill COVID-19 patients are characterized by a severe inflammatory response. Pharmacologic inhibition of acute-phase inflammatory pathways such as IL-6 receptor inhibitor, Tocilizumab (TCZ) may improve patient outcomes in these cases. Consequently, the therapeutic ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Siami, Zeinab, Hedayat Yaghoobi, Mojtaba, Karimi, Parsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657263/
https://www.ncbi.nlm.nih.gov/pubmed/38021396
http://dx.doi.org/10.47176/mjiri.37.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657263/
https://www.ncbi.nlm.nih.gov/pubmed/38021396
http://dx.doi.org/10.47176/mjiri.37.92

Ejemplares similares